China's API extortion from Indian pharma breaking down
The API coming from China started getting dumped in India at very low prices.
aurobindo pharma company
April 2024
March 2024
February 2024
December 2023
November 2023
May 2023
November 2022
August 2022
Aurobindo Pharma shares rise 2% on USFDA nod for nasal spray
The pharma company has received approval to manufacture and market Mometasone Furoate Monohydrate Nasal Spray 50 mcg, which will be launched in Q1 FY25.
Aurobindo Pharma arm to sell asset in $52 mn deal; stock dips
The deal will allow Aurobindo Pharma to enhance capacities and operations in other units.
Aurobindo Pharma arm gets US FDA nod for posaconazole injection; share up 1.6%
The product is anticipated to be launched in December 2023, the approved product is estimated to target a market size of $25.4 million.
From ₹397 to ₹1,081: This largecap pharma stock surges 170% in 10 months
The homegrown pharma company has outperformed the BSE Sensex and Healthcare index in terms of returns in the last one year.
Aurobindo Pharma shares rise 2% on USFDA approval for asthma drug
Aurobindo Pharma has received approval from USFDA to produce and trade Budesonide Inhalation Suspension
Aurobindo Pharma swings to 52-week high; here's why
The scrip opened higher at ₹1,014.95, up 0.73%, as against the previous closing price of ₹1,007.50
Aurobindo Pharma hits 52-week high despite 12% decline in PAT in Q4; here's why
In the January to March quarter this year, the company's revenues stood at ₹6,472.9 crore, up 11.4% as against ₹5,809.3 crore in the same period last year.
Aurobindo Pharma share hits a 52-week low. Here’s why
During the session, it tumbled 13.75% to hit an intraday low of ₹464. The market capitalisation of the pharmaceutical major declined to ₹28,037 crore.
Sensex, Nifty to rise as U.S. inflation cools; Eicher, CIL, Aurobindo Pharma, Bata shares eyed
The Sensex and Nifty are poised for a strong opening on upbeat global cues as a better-than-expected inflation report in the U.S. boosted investors’ appetite for riskier assets.
